Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7261MR)

This product GTTS-WQ7261MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7261MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7415MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ2587MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ3406MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ15576MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ15995MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ15616MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ799MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ2508MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW